2 Attractive High Dividend Yield Buys For Your Dividend Income Portfolio
This week, two additional companies have been added to The Dividend Income Accelerator Portfolio. Both companies pay an attractive Dividend Yield, have an appealing Valuation, and I believe their g...
2 Warren Buffett Dividend Stocks to Buy and Hold Forever
Johnson & Johnson has a stable business and one of the most impressive dividend streaks. Visa is one of the two undisputed leaders in an industry that can still grow substantially.
Why Johnson & Johnson Stock Flopped Today
Two analysts trimmed their price targets on the pharmaceutical giant. Those cuts came a day after the company's latest earnings release.
Is the "New" Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?
The healthcare giant had plenty of positives in its Q3 update. However, there are several issues to be concerned about with J&J over the next few years.
J&J's Medical Device Sales Feel the Side Effects of Weight-Loss Drugs
Riding high, Johnson & Johnson reported pharmaceutical sales worth $13.89 billion on Tuesday (Oct 17), a year-over-year growth exceeding 5%. The pharmaceuticals driving its growth are Darzalex, a ...
J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off
J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.
J&J Beats Profit Estimates on Pharmaceutical, Medtech Sales as COVID-19 Shot Revenue Slows
Johnson & Johnson (JNJ) reported better-than-anticipated results and raised its guidance as pharmaceutical and medical equipment sales gained, even with demand for its COVID-19 vaccine waning.
Johnson & Johnson Is Falling, but This Tech Stock Is Really Getting Hit Hard
Earnings season is beginning in earnest. Johnson & Johnson boosted its profit outlook on solid performance in its medical device and pharmaceutical segments.
Johnson & Johnson (JNJ) Q3 Earnings and Revenues Surpass Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.52 per share. This compares to earnings of $2.55 per share a year ago.
Johnson & Johnson CFO Joseph Wolk on Q3 results: Very well-positioned into 2024 and beyond
Johnson & Johnson CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped quarterly earnings and revenue estimates, and more.
Johnson & Johnson ups guidance as earnings top forecasts
Johnson & Johnson (NYSE:JNJ) raised guidance after a strong third quarter which saw earnings beat expectations and its product pipeline advance. The New Brunswick (NYSE:BC), New Jersey-based pharma...
J&J's stock rallies after profit and sales rise above expectations, full-year outlook increased
Shares of Johnson & Johnson JNJ, +0.43% rallied 0.8% in premarket trading Tuesday, after the drug maker and medical technology company reported third-quarter profit and sales that rose above expect...
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge
It marks J&J's first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
J&J raises annual profit forecast on anti-inflammatory drug demand
Johnson & Johnson on Tuesday raised its 2023 profit forecast, helped by resilient demand for its anti-inflammatory drug Stelara and recorded a $21 billion gain from the spin off of its consumer hea...
Johnson & Johnson earnings: What to expect
Earnings: Analysts tracked by FactSet expect J&J JNJ, +0.43% to post per-share earnings of $2.52, down from $2.55 in the year-earlier period.
Related Companies